Vir Biotechnology, Inc. (VIR)
| Market Cap | 5.52B |
| Revenue (ttm) | 75.61M |
| Net Income (ttm) | -256.79M |
| Shares Out | 125.81M |
| EPS (ttm) | -14.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $42.15 |
| Previous Close | $43.37 |
| Change ($) | -1.22 |
| Change (%) | -2.81% |
| Day's Open | 44.00 |
| Day's Range | 40.30 - 44.85 |
| Day's Volume | 1,186,941 |
| 52-Week Range | 16.26 - 60.20 |
Vir Biotechnology President and CEO explains COVID-19 antibody treatment
#coronavirusvaccine #COVID19vaccine #coronaviruspandemic Vir Biotechnology President and CEO George Scangos discusses antibody treatment and why it is going to be difficult to achieve herd imm...
The biotech announced updates about collaborations with two big partners.
Our Covid antibody treatment will work against new strains: Vir CEO
CNBC's Meg Tirrell discusses coronavirus antibody treatments in light of new Covid strains across the world with Vir CEO George Scangos at the J.P. Morgan Healthcare Conference.
– First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research –
FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clin...
SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE...
Investors need to pay close attention to in Vir Biotechnology (VIR) stock based on the movements in the options market lately.
Shares of Vir Biotechnology Inc. gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline said they started dosing patients in a late-stage clinical trial for ...
– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 –
SAN FRANCISCO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeffrey Hatfield, an accomplished industry executive with more than th...
Future Vaccines Have 'High Barrier' to Cross, Vir CEO Says
Dec.04 -- Vir Biotechnology Inc. Chief Executive Officer George Scangos says the manufacturing of vaccines is a highly regulated, complex process and the capacity to make drugs for Covid-19 is...
Competitors have already gotten emergency use authorizations from regulators and booked orders for their antibody treatments.
They'll be later to market than rivals. But if their product candidates are stronger, investors may reap rewards.
SAN FRANCISCO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, toda...
Vir Biotechnology has a deep pipeline across many disease segments, reducing concentration risk in the portfolio and expanding commercial reach. The company has key collaborations with large p...
– Manuscript highlights the importance of molecular surveillance of SARS-CoV-2 immune evasion and rational design of vaccines and antibody therapies for COVID-19 – – Manuscript highlights the ...
SAN FRANCISCO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, toda...
Two small biotechs collaborated to find a coronavirus vaccine, but one of them may come out way ahead due to its expertise and other partnerships.
SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that Phil Pang, M.D...
SAN FRANCISCO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the publication of preclinical research in an influenza animal model highlighting a new m...
Vir Biotechnology (VIR) saw a big move last session, as its shares jumped 6% on the day, amid huge volumes.
Vir Biotechnology Inc (NASDAQ: VIR) shares were rallying Tuesday after the company provided an update on its partnered COVID-19 treatment program. Vir's COVID-19 Antibody Update: Vir said it i...
The global trial of the experimental antibody therapy will expand following promising safety results in early trial participants.
Vir Biotechnology and U.K.-based partner GlaxoSmithKline said they are expanding Phase 3, or final-phase, clinical trials for a possible Covid-19 antibody treatment. VIR stock jumped.
Shares of Vir Biotechnology Inc. gained 5.3% in trading on Tuesday after the company said it is expanding the Phase 3 clinical trial for an experimental COVID-19 treatment.
Vir Biotechnology Inc. (NASDAQ: VIR) shares jumped on Tuesday after the firm announced, in conjunction with GlaxoSmithKline PLC (NYSE: GSK), that they would be expanding their late-stage COVID...
VIR, GSK begin Phase 3 trial for Covid-19 antibody drug
Vir Biotechnology and GlaskoSmithKline are expanding their coronavirus antibody drug into Phase 3 trials following positive safety and tolerability data in Phase 2. CNBC's Meg Tirrell reports.
SAN FRANCISCO and LONDON, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the...
The developers of a potential COVID-19 vaccine have moved trials to a third phase, hailing "rapid achievement" to date.
Both of these biotechs have promising COVID-19 programs. But one of them appears to have a clear edge.
– Largest -to-date analysis of serum samples from nearly 650 SARS-CoV-2-infected patients –
Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.
Investors bid its shares way up this year, but the market just slashed their value.
SAN FRANCISCO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, t...
SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, t...
SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Janet Napolitano to its board of directors. Napolitano brings a bre...
Coronavirus treatment: Glaxosmithkline partners with Vir to start antibody treatment tests
Yahoo Finance's Anjalee Khemlani reports on the latest in developments treatment for the coronavirus.
The treatment to prevent hospitalization from COVID-19 could be available in the first half of 2021.
Market Waits for Major Economic Data This Week.
GSK chief scientist and Vir CEO on clinical trial for Covid-19 antibody drug
GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients, entering the race to find a winner in a promising class of anti...
GlaxoSmithKline and Vir start phase 2/3 study for Covid-19 antibody drug
Vir Biotechnology and GlaxoSmithKline announced Monday that the first patient was dosed last week in a phase 2/3 study on an antibody drug meant for the early treatment of COVID-19 in patients...
Shares of Vir Biotechnology Inc. VIR, +1.31% gained 9.2% in premarket trading on Monday when the company and GlaxoSmithKline GSK, -0.37% said they had begun dosing patients in the Phase 2/3 cl...
GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage Covid-19 patients.
GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of anti...
SAN FRANCISCO and LONDON, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient was dosed last week...
SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, to...
Let us take a look at two small biotech companies, VIR and AUPH, which are gearing up for their earnings release.
SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, to...
SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Elliott Sigal, M.D., Ph.D., to its board of directors. Dr. Sigal for...
SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, to...
About VIR
Vir Biotechnology, a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Bios... [Read more...]
| Industry Biotechnology | IPO Date Oct 11, 2019 |
| CEO Dr. George A. Scangos | Employees 297 |
| Stock Exchange NASDAQ | Ticker Symbol VIR |
Financial Performance
In 2019, VIR's revenue was $8.09 million, a decrease of -24.16% compared to the previous year's $10.67 million. Losses were -$174.68 million, 50.7% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is 54.86, which is an increase of 30.15% from the latest price.